Haisco Pharmaceutical Group (002653.SZ): HSK45019 tablet, an innovative drug, has received acceptance of the IND application.

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisenuo Pharmaceutical Technology Co., Ltd. recently received a "Notice of Acceptance" issued by the National Medical Products Administration for the drug "HSK45019 tablets". HSK45019 is a small molecule inhibitor independently developed by the company with proprietary intellectual property rights. It is expected to provide a novel treatment method for patients with inflammatory bowel disease, bringing more convenient and effective treatment options. According to the announcement by the National Medical Products Administration on the classification of chemical drug registration and application requirements (No. 44 of 2020), this product belongs to Class 1 chemical drugs.